News Conference News SCAI 2022 Mystery MINOCA? Many COVID STEMIs Have No Culprit Lesion L.A. McKeown May 19, 2022
News Daily News NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes L.A. McKeown May 03, 2022
News Conference News ACC 2022 Managing AF Patients Undergoing PCI—Some Lingering Questions Michael O'Riordan April 12, 2022
News Conference News ACC 2022 Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events Todd Neale April 04, 2022
News Conference News ACC 2022 Bentracimab Swiftly Reverses Ticagrelor, Platelet-Function Study Affirms Todd Neale April 02, 2022
News Conference News ACC 2022 POISE-3: Tranexamic Acid Stems Bleeding During Noncardiac Surgery Todd Neale April 02, 2022
News Daily News Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention Michael O'Riordan March 30, 2022
News Conference News ACC 2022 What’s Going to Be Hot at ACC 2022, In Person or Virtual Shelley Wood March 28, 2022
News Daily News Early Aspirin Tied to Less In-Hospital Mortality in Moderate COVID-19 Todd Neale March 25, 2022
News Daily News Rare Type of Stroke More Common After SARS-CoV-2 Infection Than After mRNA Vax Todd Neale March 18, 2022
News Daily News Thrombolysis ‘Safe and Effective’ for Obstructive Mechanical Valve Thrombosis Yael L. Maxwell March 09, 2022
News Daily News Two Large Studies Affirm Rare Thrombosis Risk With ChAdOx1 COVID-19 Vax Michael O'Riordan February 23, 2022
News Daily News Even Less-Severe COVID-19 Can Have Long-term CV Effects Caitlin E. Cox February 10, 2022
News Conference News ISC 2022 ACTION-CVT: DOACs Look Like a Good Option for Cerebral Venous Thrombosis Todd Neale February 10, 2022
News Daily News Myocardial Injury Tied to Greater Mortality 1 Year After COVID-19 Hospitalization Todd Neale January 06, 2022
News Daily News FDA Approves Two Additional Indications for Rivaroxaban in Children L.A. McKeown December 21, 2021
News Daily News Adapted D-Dimer Thresholds Safe, Efficient for Acute PE Diagnosis Todd Neale December 16, 2021
News Conference News AHA 2021 No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials Todd Neale November 15, 2021